Cargando…
1578. Back to Bactrim–Utilizing Preferred Prophylaxis Strategies in Immunocompromised Hosts Via a Trimethoprim-Sulfamethoxazole Rechallenge Program
BACKGROUND: Trimethoprim sulfamethoxazole (TMP-SMX) is the preferred agent for Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised hosts (ICH). However, TMP-SMX is frequently avoided due to an adverse drug reaction (ADR) history. We report on a novel multicentre programmatic approach t...
Autores principales: | Smibert, Olivia, Urbancic, Karen, Douglas, Abby, Devchand, Misha, Slavin, Monica, Trubiano, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252477/ http://dx.doi.org/10.1093/ofid/ofy210.1406 |
Ejemplares similares
-
1787. The Safety and Efficacy of an Oral Penicillin Rechallenge Program in Cancer Patients: A Pilot Multicenter Study
por: Smibert, Olivia, et al.
Publicado: (2018) -
Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review
por: Haseeb, Abdul, et al.
Publicado: (2022) -
Hyponatremia after initiation and rechallenge with trimethoprim–sulfamethoxazole in an older adult
por: Huntsberry, Ashley M, et al.
Publicado: (2015) -
Methemoglobinemia in a Pediatric Oncology Patient Receiving Sulfamethoxazole/Trimethoprim Prophylaxis
por: Carroll, Timothy G., et al.
Publicado: (2016) -
1592. Safety of Oral Trimethoprim/Sulfamethoxazole Prophylaxis in Renal Transplant Recipients
por: Horvat, Courtney, et al.
Publicado: (2018)